Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 78, Issue 1-2, 2018, Pages 109-113

  Aasbrenn, Martin ^a,b   Valeur, Jørgen ^c   Farup, Per G ^a,b  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c LOVISENBERG DIAKONALE HOSPITAL   (Norway)

Author keywords

Biomarkers; diagnostic tests; dysbiosis; gastrointestinal diseases; irritable bowel syndrome; microbiota; morbid obesity; obesity

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DYSBIOSIS; FAECAL DYSBIOSIS TEST; FECES MICROFLORA; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; COMPLICATION; FECES; MICROBIOLOGY; MIDDLE AGED; OBESITY; PREVALENCE;

ADULT; DYSBIOSIS; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OBESITY; PREVALENCE;

EID: 85038859799     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365513.2017.1419372     Document Type: Article

References (23)

1. Ford AC, Lacy BE, Talley NJ., Irritable bowel syndrome. N Engl J Med. 2017;376:2566–2578.
2. Camilleri M., Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther. 2015;42:818–828.
3. Sood R, Gracie DJ, Law GR, et al. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42:491–503.
4. Lynch SV, Pedersen O., The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–2379.
5. TM Dysbiosis Test [Internet]. Oslo: Genetic Analysis; 2016 [cited 2017 Nov 11]. Available from: http://www.genetic-analysis.com/ga-map-dysbiosis-test
6. Major G, Spiller R., Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes. 2014;21:15–21.
7. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546.
8. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
9. Palleja A, Kashani A, Allin KH, et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med. 2016;8:67.
10. Zhuang X, Xiong L, Li L, et al. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:28–38.
11. Casen C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42:71–83.
12. Bennet SMP, Böhn L, Störsrud S, et al. Multivariate modelling of faecal bacterial profilse of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut. 2017. doi: 10.1136/gutjnl-2016-313128.
13. Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2009;18:190–195.
14. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115:956–961.
15. Ricanek PV, Vatn S, Kalla R, et al. The Ibd-Character Consortium. Microbiota Alterations in Treatment Naïve IBD and Non-IBD Patients - the EU IBD-Character Project. United European Gastroenterol J. 2016;4:A95.
16. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
17. Francis CY, Morris J, Whorwell PJ., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Alimentary Pharmacol Ther. 1997;11:395–402.
18. Sauar J, Halvorsen F, Corwin C, Olafsson S., Dysbiosis and stability over two years in patients with irritable bowel syndrome. United European Gastroenterology J. 2016;4(Supplement 1):A524.
19. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–564.
20. Portney LG, Watkins MP., Foundations of Clinical Research Applications to Practice. Upper Saddle River (NJ): Pearson International Edition 2009. Statistical measures of validity, p. 619–658.
21. Vebø HC, Sekelja M, Nestestog R, et al. Temporal development of the infant gut microbiota in immunoglobulin E-sensitized and nonsensitized children determined by the GA-map infant array. Clin Vaccine Immunol. 2011;18:1326–1335.
22. Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. ECCOJC. 2016;10:943–952.
23. Hansen TH, Gøbel RJ, Hansen T, et al. The gut microbiome in cardio-metabolic health. Genome Med. 2015;7:33.